Literature DB >> 17047980

Factors affecting the stability of visual function following cessation of occlusion therapy for amblyopia.

Daniel J Tacagni1, Catherine E Stewart, Merrick J Moseley, Alistair R Fielder.   

Abstract

AIM: To identify factors that predict which children with amblyopia are at greatest risk of regression of visual acuity (VA) following the cessation of occlusion therapy.
METHOD: A retrospective analysis was performed of 182 children (mean age at cessation of treatment; 5.9+/-1.6 years) who had undergone occlusion therapy for unilateral amblyopia, and had been followed up at least once within 15 months of cessation. Statistical analysis was used to identify whether change in VA following treatment cessation had any association with various factors, including the child's age, type of amblyopia, degree of anisometropia, initial severity of amblyopia, binocular vision status, length and dose of occlusion therapy, and VA response to treatment.
RESULTS: At 1 year, follow-up from treatment cessation, children with "mixed" amblyopia (both anisometropia and strabismus) demonstrated significantly (p=0.03) greater deterioration in VA (0.11+/-0.11 log units) than children with only anisometropia (0.02+/-0.08 log units) or only strabismus (0.05+/-0.10 log units). However, none of the other factors investigated were found to be significant predictors.
CONCLUSION: This study supports previous research that it is possible to identify those children most at risk of deterioration in VA following cessation of occlusion therapy. The presence of mixed amblyopia was the only risk factor identified in this study. Management of amblyopia should take this into account, with a more intensive follow-up recommended for those with both anisometropia and strabismus (mixed) amblyopia.

Entities:  

Mesh:

Year:  2006        PMID: 17047980     DOI: 10.1007/s00417-006-0395-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  14 in total

1.  Follow-up results of occlusion and pleoptic treatment.

Authors:  S R Malik; P S Virdi; B K Goel
Journal:  Acta Ophthalmol (Copenh)       Date:  1975-09

2.  The period of susceptibility to the physiological effects of unilateral eye closure in kittens.

Authors:  D H Hubel; T N Wiesel
Journal:  J Physiol       Date:  1970-02       Impact factor: 5.182

3.  Long-term follow-up of occlusion therapy in amblyopia.

Authors:  H Leiba; M Shimshoni; M Oliver; N Gottesman; S Levartovsky
Journal:  Ophthalmology       Date:  2001-09       Impact factor: 12.079

4.  When is it safe to stop patching?

Authors:  J G Oster; J W Simon; P Jenkins
Journal:  Br J Ophthalmol       Date:  1990-12       Impact factor: 4.638

5.  Risk of amblyopia recurrence after cessation of treatment.

Authors:  Jonathan M Holmes; Roy W Beck; Raymond T Kraker; William F Astle; Eileen E Birch; Stephen R Cole; Susan A Cotter; Sean Donahue; Donald F Everett; Richard W Hertle; Ronald V Keech; Evelyn Paysse; Graham F Quinn; Michael X Repka; Mitchell M Scheiman
Journal:  J AAPOS       Date:  2004-10       Impact factor: 1.220

6.  Long-term effect of hypermetropic anisometropia on the visual acuity of treated amblyopic eyes.

Authors:  S Levartovsky; M Oliver; N Gottesman; M Shimshoni
Journal:  Br J Ophthalmol       Date:  1998-01       Impact factor: 4.638

7.  Long term visual outcome in amblyopia treatment.

Authors:  J Ohlsson; M Baumann; J Sjöstrand; M Abrahamsson
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

8.  A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children.

Authors:  Jonathan M Holmes; Raymond T Kraker; Roy W Beck; Eileen E Birch; Susan A Cotter; Donald F Everett; Richard W Hertle; Graham E Quinn; Michael X Repka; Mitchell M Scheiman; David K Wallace
Journal:  Ophthalmology       Date:  2003-11       Impact factor: 12.079

9.  A randomized trial of patching regimens for treatment of moderate amblyopia in children.

Authors:  Michael X Repka; Roy W Beck; Jonathan M Holmes; Eileen E Birch; Danielle L Chandler; Susan A Cotter; Richard W Hertle; Raymond T Kraker; Pamela S Moke; Graham E Quinn; Mitchell M Scheiman
Journal:  Arch Ophthalmol       Date:  2003-05

10.  Practical management of amblyopia.

Authors:  F C Ching; M M Parks; D S Friendly
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1986 Jan-Feb       Impact factor: 1.402

View more
  7 in total

Review 1.  Clinical and experimental advances in congenital and paediatric cataracts.

Authors:  Amanda Churchill; Jochen Graw
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-04-27       Impact factor: 6.237

2.  The Need for a Unified Protocol for Termination of Amblyopia Treatment.

Authors:  Mahmoud M Nassar; Fiona Campbell Mitchell
Journal:  Br Ir Orthopt J       Date:  2018-04-24

3.  Can Short-Term Ocular Dominance Plasticity Provide a General Index to Visual Plasticity to Personalize Treatment in Amblyopia?

Authors:  Chunwen Tao; Zhifen He; Yiya Chen; Jiawei Zhou; Robert F Hess
Journal:  Front Neurosci       Date:  2020-06-26       Impact factor: 4.677

Review 4.  The challenges of amblyopia treatment.

Authors:  Gail D E Maconachie; Irene Gottlob
Journal:  Biomed J       Date:  2016-02-28       Impact factor: 4.910

Review 5.  Simplified updates on the pathophysiology and recent developments in the treatment of amblyopia: A review.

Authors:  Santhan K S Gopal; Jai Kelkar; Aditya Kelkar; Abhishek Pandit
Journal:  Indian J Ophthalmol       Date:  2019-09       Impact factor: 1.848

6.  Fixational eye movements abnormalities and rate of visual acuity and stereoacuity improvement with part time patching.

Authors:  Matteo Scaramuzzi; Jordan Murray; Paolo Nucci; Aasef G Shaikh; Fatema F Ghasia
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

7.  Factors predicting recurrence in successfully treated cases of anisometropic amblyopia.

Authors:  Rohit Saxena; Shraddha Puranik; Digvijay Singh; Vimla Menon; Pradeep Sharma; Swati Phuljhele
Journal:  Indian J Ophthalmol       Date:  2013-11       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.